Loading…
This event has ended. View the official site or create your own event → Check it out
This event has ended. Create your own

For Campus Prearrival Information <click here>
For a PDF of the 2015 Program Materials <click here>
For ALL Abstracts [1-220] in sequential order <click here>
For ALL Authors of the Lecture and Poster Presentations <click here>


View analytic
Thursday, August 27 • 4:00pm - 4:20pm
[0217] Synthesis and Conformational Studies of Small Molecule Macrocyclic Inhibitors of ALK/ROS1 – Discovery of PF-06463922

Sign up or log in to save this to your schedule and see who's attending!

Limited Capacity seats available

This talk will focus on the synthesis of the chemical properties of the macrocyclic inhibitors developed for the EML4 ALK program for the treatment of NSCLC leading to the discovery of the clinical candidate PF-06463922. The work disclosed will feature (i) variations of the heterocyclic tailpiece of the molecule, and the synthetic chemistry to incorporate these into the macrocyclic ring through either macrolactamization or direct arylation, (ii) conformational studies and atropisomerism of specific macrocyclic ring systems, and (iii) optimization and scale-up of the clinical candidate including the evolution of the synthesis of the pyrazole tailpiece.


ST Lecturers
avatar for Paul Richardson

Paul Richardson

Pfizer
Senior Principal Scientist, Pfizer, La Jolla



Thursday August 27, 2015 4:00pm - 4:20pm
Girvetz 2119